1025 related articles for article (PubMed ID: 26937129)
1. Advanced gastric cancer: Current treatment landscape and future perspectives.
Digklia A; Wagner AD
World J Gastroenterol; 2016 Feb; 22(8):2403-14. PubMed ID: 26937129
[TBL] [Abstract][Full Text] [Related]
2. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.
Janmaat VT; Steyerberg EW; van der Gaast A; Mathijssen RH; Bruno MJ; Peppelenbosch MP; Kuipers EJ; Spaander MC
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD004063. PubMed ID: 29182797
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment of metastatic gastric cancer: Current options and future directions.
Kanagavel D; Fedyanin M; Tryakin A; Tjulandin S
World J Gastroenterol; 2015 Nov; 21(41):11621-35. PubMed ID: 26556991
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
5. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
6. Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy.
Izuishi K; Mori H
J Gastrointestin Liver Dis; 2016 Mar; 25(1):87-94. PubMed ID: 27014758
[TBL] [Abstract][Full Text] [Related]
7. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
Jørgensen JT
World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy for advanced gastric cancer--our possibilities in 2007].
Dank M; Torgyík L; Szentmártoni G
Magy Onkol; 2007; 51(3):209-17. PubMed ID: 17922060
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.
Miceli R; Tomasello G; Bregni G; Di Bartolomeo M; Pietrantonio F
World J Gastroenterol; 2014 Apr; 20(16):4516-25. PubMed ID: 24782604
[TBL] [Abstract][Full Text] [Related]
10. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Bilici A
World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
[TBL] [Abstract][Full Text] [Related]
11. Molecular-targeted first-line therapy for advanced gastric cancer.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011461. PubMed ID: 27432490
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.
Zou K; Yang S; Zheng L; Yang C; Xiong B
BMC Cancer; 2016 Sep; 16(1):737. PubMed ID: 27633381
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
14. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies in Advanced Gastric Cancer.
Patel TH; Cecchini M
Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
[TBL] [Abstract][Full Text] [Related]
17. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
18. Advanced gastric cancer: is there enough evidence to call second-line therapy standard?
Arkenau HT; Saggese M; Lemech C
World J Gastroenterol; 2012 Nov; 18(44):6376-8. PubMed ID: 23197882
[TBL] [Abstract][Full Text] [Related]
19. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
20. Advancing pharmacological treatment options for advanced gastric cancer.
Sudo K; Yamada Y
Expert Opin Pharmacother; 2015; 16(15):2293-305. PubMed ID: 26359224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]